MDR Klebsiella pneumoniae ST307 is a high-risk clone, whose genetic features contribute to its adaptation to hospital environments and the human host. This study describes the emergence and clonal dissemination of K. pneumoniae ST307, recovered during November 2018 to February 2019 in a hospital in Buenos Aires city, which concurrently harbored KPC-3 and NDM-1. These isolates were resistant to all β-lactams and to the ceftazidime/avibactam combination. Molecular studies showed that bla was located in Tn4401a platform, while bla was surrounded upstream by ISKpn14 followed by a partial sequence of ISAba125 and downstream by bleMBL-trpF, located in a 145.5kb conjugative plasmid belonging to the Inc A/C group. The dissemination of K. pneumoniae ST307 isolates co-producing KPC-3 and NDM-1 could lead to a worrisome scenario due to the remarkable features of this clone and its resistance profile.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ram.2022.04.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Virulence profile of carbapenem-resistant strains by an model of .
Microbiol Spectr
January 2025
Microbiology and Virology, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
is a significant healthcare-associated pathogen, notable for its diverse virulence and antibiotic resistance profiles. This study aimed to characterize the genotypic and phenotypic diversity of isolates and evaluate their virulence using the model. Biomass production, metabolic activity, capsule formation, and siderophore production were assessed in 27 .
View Article and Find Full Text PDFRapidly spreading with OXA-48-like carbapenemases.
J Clin Microbiol
January 2025
Division of Microbiology, Alberta Precision Laboratories, Calgary, Alberta, Canada.
(mostly , ) with OXA-48-like carbapenemases (e.g., OXA-48, -181, -232, -244) are undermining the global efficiency of carbapenem therapy.
View Article and Find Full Text PDFCarbapenemase-Producing Enterobacterales from Patients Arriving from Ukraine in Poland, March 2022-February 2023.
Infect Dis Ther
January 2025
Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Chełmska 30/34, 00-725, Warsaw, Poland.
Introduction: Despite a scarcity of data, before 2022 Ukraine was already considered a high-prevalence country for carbapenemase-producing Enterobacterales (CPE), and the situation has dramatically worsened during the full-scale war with Russia. The aim of this study was to analyse CPEs isolated in Poland from victims of war in Ukraine.
Methods: The study included 65 CPE isolates from March 2022 till February 2023, recovered in 36 Polish medical centres from 57 patients arriving from Ukraine, differing largely by age and reason for hospitalisation.
Prevalence and molecular characteristics of colistin-resistant isolates among carbapenem-resistant Klebsiella pneumoniae in Central South China: a multicenter study.
Ann Clin Microbiol Antimicrob
January 2025
Department of Clinical Laboratory, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, Hunan, China.
Background: The emergence of colistin resistance in carbapenem-resistant Klebsiella pneumoniae (CRKP) is a significant public health concern, as colistin has been the last resort for treating such infections. This study aimed to investigate the prevalence and molecular characteristics of colistin-resistant CRKP isolates in Central South China.
Methods: CRKP isolates from twelve hospitals in Central South China were screened for colistin resistance using broth microdilution.
High activity and specificity of bacteriophage cocktails against carbapenem-resistant belonging to the high-risk clones CG258 and ST307.
Front Microbiol
December 2024
Grupo de Investigación en Microbiología Básica y Aplicada (MICROBA), Escuela de Microbiología, Universidad de Antioquia, Medellín, Colombia.
Introduction: The widespread clinical and environmental dissemination of successful clones of carbapenem-resistant (CRKP) represents a serious global public health threat. In this context, lytic bacteriophages have emerged as a promising alternative for controlling these pathogens. This study describes the biological, structural, and genomic characteristics of lytic bacteriophages against the high-risk CRKP clones CG258 and ST307 and describes their performance in combination.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!